Application of allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia in the era of targeted therapy / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 11-15, 2022.
Artigo
em Chinês
| WPRIM
| ID: wpr-929724
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the main curable therapies for patients with acute lymphoblastic leukemia (ALL). This article discusses the status of allo-HSCT for ALL as well as how to combine targeted therapy with allo-HSCT to improve outcomes of ALL in the era of targeted therapy based on the data obtained from the 63rd American Society of Hematology (ASH) Annual Meeting.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS